In the current study, the lungs of bleomycin-treated mice had elevated levels of LOX and LOXL2 protein when compared to vehicle-treated animals 21 days after bleomycin dosage (Figure 3A), consistent with the elevated LOX and LOXL2 expression found in lungs of the SSc patients. Here, LOXL2 is linked to systemic sclerosis.